Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Mesquita, Pedro M M ^a   Srinivasan, Priya ^b   Johnson, Todd J ^c   Rastogi, Rachna ^c   Evans Strickfaden, Tammy ^b   Kay, Michael S ^d   Buckheit, Karen W ^e   Buckheit, Robert W ^e   Smith, James M ^b   Kiser, Patrick F ^c   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c University of Utah   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e ImQuest Biosciences   (United States)

Author keywords

HIV; Intravaginal ring; Microbicide; Pre Exposure Prophylaxis; Preclinical models

Indexed keywords

D PEPTIDE CHOL PIE 12 TRIMER; DAPIVIRINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; IQP 0528; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROTECTION; CLADISTICS; COCULTURE; COITUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BIOAVAILABILITY; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG SCREENING; DRUG TRANSPORT; EX VIVO STUDY; EXPLANT; GEL; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFECTION PREVENTION; INTRAVAGINAL RING; MACACA; NONHUMAN; PHARMACODYNAMICS; PRE EXPOSURE PROPHYLAXIS; PROPHYLAXIS; SEMINAL PLASMA; T LYMPHOCYTE; TOPICAL TREATMENT; UTERINE CERVIX BIOPSY; UTERINE CERVIX CYTOLOGY; VIRUS INHIBITION;

ANIMALIA; MACACA;

ANIMALS; ANTI-HIV AGENTS; CHEMOPREVENTION; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DISEASE TRANSMISSION, INFECTIOUS; DRUG EVALUATION, PRECLINICAL; FEMALE; HIV INFECTIONS; MACACA; ORGAN CULTURE TECHNIQUES; T-LYMPHOCYTES;

EID: 84886051506     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-113     Document Type: Article

References (36)

1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012, 367:399-410. 10.1056/NEJMoa1108524, 3770474, 22784037.
2. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012, 367:423-434. 10.1056/NEJMoa1110711, 22784038.
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2599. 10.1056/NEJMoa1011205, 3079639, 21091279.
4. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61127-7/abstract.
5. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012, 367:411-422. 10.1056/NEJMoa1202614, 3687217, 22784040.
6. MTN Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women http://www.mtnstopshiv.org/sites/default/files/attachments/finalMTNstatementSept16DSMB_0.pdf.
7. Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav 2013, 17:2143-2155. 10.1007/s10461-013-0429-9, 3672509, 23435697.
8. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174. 10.1126/science.1193748, 3001187, 20643915.
9. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, Taljaard M, Piper J, Gomez FK, Chirenje M, Team VS. Paper #26LB: Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) 2013, Atlanta, GA, USA: Georgia World Congress Center.
10. Keller MJ, Mesquita PM, Torres NM, Cho S, Shust G, Madan RP, Cohen HW, Petrie J, Ford T, Soto-Torres L, et al. Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One 2010, 5:e8781. 10.1371/journal.pone.0008781, 2809740, 20107502.
11. Patel S, Hazrati E, Cheshenko N, Galen B, Yang H, Guzman E, Wang R, Herold BC, Keller MJ. Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis 2007, 196:1394-1402. 10.1086/522606, 17922405.
12. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010, 376:1329-1337. 10.1016/S0140-6736(10)61086-0, 2956883, 20851460.
13. Sharkey DJ, Tremellen KP, Jasper MJ, Gemzell-Danielsson K, Robertson SA. Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol 2012, 188:2445-2454. 10.4049/jimmunol.1102736, 22271649.
14. Mesquita PM, Rastogi R, Segarra TJ, Teller RS, Torres NM, Huber AM, Kiser PF, Herold BC. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother 2012, 67(7):1730-8. 10.1093/jac/dks097. Epub 2012 Mar 30, 10.1093/jac/dks097, 3370818, 22467632.
15. Smith J, Rastogi R, Teller R, Srinivasan P, Mitchell J, McNicholl J, Hendry R, Mesquita P, Kiser P, Herold B. Paper #25LB: A Tenofovir Disoproxil Fumarate Intravaginal Ring Completely Protects against Repeated SHIV Vaginal Challenge in Nonhuman Primates. 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) 2013, Atlanta, GA, USA: Georgia World Congress Center.
16. Johnson TJ, Srinivasan P, Albright TH, Watson-Buckheit K, Rabe L, Martin A, Pau CP, Hendry RM, Otten R, McNicholl J, et al. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 2012, 56:1291-1299. 10.1128/AAC.05721-11, 3294899, 22155820.
17. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, Romano J. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009, 51:416-423. 10.1097/QAI.0b013e3181acb536, 19623693.
18. Gupta KM, Pearce SM, Poursaid AE, Aliyar HA, Tresco PA, Mitchnik MA, Kiser PF. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci 2008, 97:4228-4239. 10.1002/jps.21331, 18338805.
19. Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mollendorf C, Geubbels E, Vyankandondera J, Rees HV, Masenga G, Kiwelu I, et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009, 23:1531-1538. 10.1097/QAD.0b013e32832c413d, 19550287.
20. Francis JN, Redman JS, Eckert DM, Kay MS. Design of a modular tetrameric scaffold for the synthesis of membrane-localized d-peptide inhibitors of HIV-1 entry. Bioconjug Chem 2012, 23(6):1252-1258. 10.1021/bc300076f.
21. Mesquita PM, Rastogi R, Segarra TJ, Teller RS, Torres NM, Huber AM, Kiser PF, Herold BC. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother 2012, 67:1730-1738. 10.1093/jac/dks097, 3370818, 22467632.
22. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 2011, 66:240-250. 10.1093/jac/dkq447, 3019086, 21118913.
23. Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, Ecker GF, Faller B, Fischer H, Gerebtzoff G, et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 2010, 9:597-614. 10.1038/nrd3187, 20671764.
24. Gustafsson SS, Vrang L, Terelius Y, Danielson UH. Quantification of interactions between drug leads and serum proteins by use of "binding efficiency" Anal Biochem 2011, 409:163-175. 10.1016/j.ab.2010.10.028, 21036137.
25. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49:4721-4732. 10.1128/AAC.49.11.4721-4732.2005, 1280117, 16251317.
26. Dezzutti CS, Uranker K, Bunge KE, Richardson-Harman N, Macio I, Hillier SL. HIV-1 infection of female genital tract tissue for use in prevention studies. J Acquir Immune Defic Syndr 2013, 63(5):548-554. Mar 19. 15 August 2013, 10.1097/QAI.0b013e318291f331, 23514957.
27. McGowan I, Tanner K, Elliott J, Ibarrondo J, Khanukhova E, McDonald C, Saunders T, Zhou Y, Anton PA. Nonreproducibility of "snap-frozen" rectal biopsies for later use in ex vivo explant infectibility studies. AIDS Res Hum Retroviruses 2012, 28:1509-1512. 10.1089/aid.2012.0062, 3484788, 22831398.
28. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006, 19:1-7. 10.1097/01.qco.0000200293.45532.68, 16374210.
29. Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, Tressler R, Sloan RD, Wainberg MA. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob Agents Chemother 2012, 56:4154-4160. 10.1128/AAC.00409-12, 3421589, 22615275.
30. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004, 10:315-336. 10.2174/1381612043386374, 14754390.
31. Shattock RJ, Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med 2012, 2:a007385. 10.1101/cshperspect.a007385, 3281595, 22355798.
32. Harrison PF, Rosenberg Z, Bowcut J. Topical microbicides for disease prevention: status and challenges. Clin Infect Dis 2003, 36:1290-1294. 10.1086/374834, 12746775.
33. Mesquita PM, Wilson SS, Manlow P, Fischetti L, Keller MJ, Herold BC, Shattock RJ. Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol 2008, 82:6576-6584. 10.1128/JVI.00335-08, 2447100, 18434407.
34. Madan RP, Mesquita PM, Cheshenko N, Jing B, Shende V, Guzman E, Heald T, Keller MJ, Regen SL, Shattock RJ, Herold BC. Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol 2007, 81:7636-7646. 10.1128/JVI.02851-06, 1933367, 17494078.
35. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000, 74:5577-5586. 10.1128/JVI.74.12.5577-5586.2000, 112045, 10823865.
36. Promadej-Lanier N, Smith JM, Srinivasan P, McCoy CF, Butera S, Woolfson AD, Malcolm RK, Otten RA. Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates. Journal of medical primatology 2009, 38:263-271. 10.1111/j.1600-0684.2009.00354.x, 19476564.